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Hereditary haemorrhagic telangiectasia
(HHT), associated with arteriovenous malforma-
tions, is a genetic disease of the vascular system
with a frequency of approx.  1:10,000. Genetic di-
agnosis serves to identify individuals at risk of de-
veloping the disease and is a useful tool for ge-
netic counselling purposes.
Questions under study: Here we report on a
child presenting severe arteriovenous malforma-
tions leading to heart failure. Her mother and
grandmother present fewer symptoms of heredi-
tary haemorrhagic telangiectasia. In this study we
identify the cause of HHT in the family.
Methods: Clinical examination, PCR, DNA
sequencing, quantitative PCR, Southern blot, x-
ray, ultrasound, cardiac catheterisation and angio-
cardiography.
Results: Initially the sequence variant in
c.392C>T in the endoglin gene was detected in
the grandmother, but not in other affected family
members. Further analyses revealed a deletion of
exon 1 of endoglin, segregating with the pheno-
type. 
Conclusions: This report points out the need
for careful evaluation of molecular genetic find-
ings, particularly in diseases with highly variable
phenotype.
Key words: Osler-Weber-Rendu; mutation; gene
polymorphisms; heart hypertrophy; epistaxis; telangiec-
tasia
Summary
Hereditary haemorrhagic telangiectasia
(HHT) is an autosomal dominant disorder mani-
fested in about 1/10,000 individuals [1]. The lead-
ing criteria for the clinical diagnosis in patients
with HHT are recurrent nosebleeds, cutaneous
telangiectases, internal arteriovenous malforma-
tions (AVMs) and positive family history. At least
3 out of these 4 criteria are necessary to establish
a definite clinical diagnosis. However, age of onset
and severity of symptoms are highly variable even
in affected members of the same family. Individu-
als may remain undiagnosed until a life-threaten-
ing complication occurs. AVMs may occur in the
lungs, liver, central nervous system or, rarely, in
other organs, leading to stroke, various haemor-
rhages and severe anaemia. Mutations in at least
three genes are causally related to HHT [2, 3, 5].
Mutations in the endoglin (ENG; OMIM 187300)
gene are associated with a high prevalence of
 pulmonary AVMs [4], whereas mutations in the
activin receptor-like kinase-1 gene (ACVRL1; ALK-1,
OMIM 600376) are linked to a lower frequency
of pulmonary and cerebral AVMs but to a higher
incidence of liver involvement [4]. Additionally,
mutations in an unidentified third gene linked to
chromosome 5, as well as mutations in SMAD4
(also: MADH4, OMIM 600993) are likely to ac-
count for some HHT cases [5]. (Mutations in
SMAD4 are also known to cause a combined syn-
drome of HHT and juvenile polyposis [6]). The
large number of truncating mutations in HHT1,
together with experimental evidence [7, 8], point
to haploinsufficiency as the main causative mech-
anism for HHT mutations.
Introduction
List of abbreviations (not explained in text)
OMIM Online Mendelian inheritance in man
PCR Polymerase chain reaction
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Blood samples from an affected family underwent
molecular genetic analyses in the Institute of Human
 Genetics, Göttingen. A pedigree is given in Fig. 1. The
 molecular diagnosis for every patient analysed was con-
ducted after the referring physician had received consent.
Written consent for anonymous publication of the study
was obtained from all family members analysed. Consent
for the newborn child was obtained from the parents.
Genomic DNA was isolated from peripheral blood
leucocytes. The coding regions of both endoglin and
ACVRL1 were amplified on a PTC-100™ thermal cycler
(MJ Research, Waltham, USA) (primer sequences are
available on request). Polymerase chain reaction products
were purified with Millipore Microcon PCR Filter tubes
(Milian SA, Geneva, Switzerland) and were directly
 sequenced in both directions on an Amersham
MEGABACE® DNA Sequencer. Sequence variations
were tested in 50 unrelated control individuals from the
same ethnic background. The detection of deletions was
performed in both endoglin and ACVRL1 by quantita-
tive PCR [9]. The analysis was conducted on the ABI
Prism 7900 Sequence Detection System (PE Applied
Biosystems and 384-well plates from AB gene, Hamburg,
Germany). The results were analysed using the Sequence
Detection System software (SDS version 2.0, PE Applied
Biosystems). We used the same reaction reagents, con-
centrations and quantitative PCR conditions as described
by Boehm et al. [9]. Primer sequences are available on re-
quest. For detection of the exact deletion length a three-
step approach was selected: as a first step, 3 amplicons for
ACVRL1 and 5 amplicons for endoglin were designed,
spanning the whole genomic sequence of the genes. Once
a deletion could be detected, 6 further amplicons were
designed in a second step, 3 in the 5’ region of the ini-
tially deleted amplicon and 3 in its 3’ region. After nar-
rowing of the 5’ and 3’ breakpoints, several primers were
designed in the putative breakpoint regions. As the third
step, non-quantitative PCRs were conducted with vari-
ous primer combinations from the putative breakpoint
regions. The conditions for these PCRs were: denatura-
tion at 95 ºC for 15 min, denaturation at 95 ºC for 30 sec-
onds, annealing at 60 ºC for 1 min, elongation at 72 ºC
for 2 min, the latter 3 repeated for 35 cycles. A longer
elongation time in comparison with standard PCR condi-
tions was selected to allow amplification for longer am-
plicons also (up to about 2kb). Due to the great distance
between the F and R primer on undeleted wildtype ge-
nomic DNA, only DNA from the deleted allele could be
amplified during this last step. The product of this “dele-
tion-specific PCR” was then sequenced as mentioned
above. A comparison of the provided sequence with the
sequence published on the NCBI webpage was per-
formed to provide the 5’ and 3’ breakpoints. 
The advantage of the approach described is that it
provides relatively rapid identification of breakpoints
without the need to clone genomic DNA to separate the
wildtype from the deleted allele. To confirm the deletion
by an independent method we performed a Southern blot
analysis. For this purpose, SacI digested DNA was elec-
trophoresed on a 0.7% agarose gel at 25 V for 24 h. Gels
were blotted onto Hybond-XL membranes in 20×SSC
overnight. Filters were baked for 1 h at 80 °C. For hy-
bridisation a 700 bp fragment of intron 1 of endoglin
gene was amplified by PCR. The PCR fragment was
cloned in the pGEM T-Easy vector (Promega) and then
extracted with EcoRI restriction enzyme. The gel-ex-
tracted fragment of the endoglin gene was labeled with
32P-dCTP using the Rediprime II system (Amersham
Pharmacia). Filters were hybridised with the probe in
Rapid-hyb buffer (Amersham Pharmacia) with 100
μg/mL denatured salmon sperm DNA at 65 °C for 16 h.
Filters were washed at room temperature in 2× SSC,
0.2% SDS for 15 min followed by 15 min in 0.5× SSC,
0.2% SDS at 65 °C, and were then exposed with x-ray
film for 24h.
Patients, material and methods
Figure 1
Pedigree of the fam-
ily with the novel en-
doglin deletion. Cir-
cles symbolise
 females, squares
males, shadow sym-
bolises clinical symp-
toms of HHT. Num-
bers out of brackets
below symbols sym-
bolise age. Arrows in-
dicate individuals
who were tested for
mutations. The muta-
tions found are repre-
sented next to each
person on pedigree.
WT: wildtype E: spon-
taneous and recur-
rent epistaxis, 
T: telangiectases,
AVM: arteriovenous
malformation, 
P: pulmonary, 
AB: intraabdominal,
SP: spinal, GI: gas-
trointestinal. 
III-(1) is not shad-
owed, because
 initially she was not
 diagnosed with HHT.
Results
As the second child of a now 28-year-old
healthy mother (III-1) the affected girl (IV-2) was
born without complications at 39 weeks gesta-
tional age (see fig. 1 for pedigree). The birth
weight was 2680 g (5th perc.) and Apgar score was
10/10 after 5 and 10 minutes respectively. The girl
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presented epistaxis for the first time at the age of
three weeks. A paediatrician was consulted after
another episode of epistaxis at the age of 14
weeks. At that time the girl was cyanotic and oxy-
gen saturation was measured at 75% in room air.
Cyanotic heart failure was ruled out by ultra-
sound. Tachypnoea and elevated density in chest
x-ray prompted an initial diagnosis of pneumonia.
Further examination with ultrasound of the ab-
domen revealed increased blood flow in the portal
vein. This proved to be due to an arteriovenous
anastomosis between splenic artery and portal
vein. Cardiac catheterisation and angiocardiogra-
phy revealed multiple arteriovenous fistulas of the
pulmonary vessels. Implantation of 21 coil devices
to block the blood flow into these AVMs (fig. 3)
improved saturation in the systemic arteries to
90%. At the age of 7 months laser coagulation had
to be administered to the nasal mucous mem-
brane. Due to gastrointestinal hemorrhages an
Figure 2
A + B: Southern blot
analysis of genomic
DNA isolated from
blood. Upon diges-
tion with Sac1, the
wildtype allele gives
rise to a 6.9kb frag-
ment, while the DNA
of IV-(2) generates
the 6.9kb and 5.4
fragments, detected
with a 3´probe lo-
cated in intron1 (Wt:
wildtype). C: Dele-
tion-specific sequenc-
ing of the affected al-
lele depicts the re-
gions 5’ and 3’ from
the deletion (10064
bases including exon
1 with ATG codon are
deleted) and het-
erozygous c.392C>T
mutation in exon 4 of
the endoglin gene.
Figure 3
On the left, chest 
x-ray at the age of 14
weeks depicting car-
diac hypertrophy; in
the middle, chest 
x-ray at the age of 20
months, after multiple
coil  implantation; on
the right, T2 MRT of
the spinal cord (at 
the age of 2 years)
depicting a large ar-
teriovenous malfor-
mation at the level 
of the 6th thoracic
spinal body.
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endoscopic intervention was necessary at the age
of ten months. The source was telangiectasia in
the ascending colon. Cerebral bleeding due to a
cerebral AVM was the reason for a prolonged
half-side seizure at the age of 21 months. Before
the age of 21 months, the underlying cerebral
AVM had not evidenced itself, which is why no
brain CT or arterial angiography was performed
earlier. After detection of the cerebral AVM,
MRT of the spine was performed to detect or ex-
clude further AVMs of the central nervous system.
A large arteriovenous malformation at the level of
the 6th thoracic spinal body (fig. 3) was detected,
which, interestingly enough, creates no neurolog-
ical problems.
The grandmother (II-2) of the affected girl
had been diagnosed with HHT. Due to this previ-
ous history of HHT in the family, HHT was sug-
gested as the most probable diagnosis for the girl,
although her mother (III-1) seemed to be unaf-
fected initially (25 years old at birth of the child).
At 26 years, however, spontaneous and recurrent
epistaxes presented for the first time. Even after
clinical examination by a dermatologist no mu-
cosal or cutaneous telangiectases were detected.
Further ultrasound and MRT examinations and
central nervous system arteriographies are now
planned to detect possible AVMs preclinically.
Initially the disease causing mutation in the fam-
ily was thought to be the c.392C>T in the en-
doglin gene, which is also cited in published re-
ports disease causing [10]. Because it was not
found in the girl’s genomic DNA, the girl was 
expected to have another mutation in endoglin or
ACVRL1 or another disease with symptoms 
resembling HHT (e.g. OMIM entities 108010,
608354). Since direct sequencing does not reveal
large rearrangements, we decided to perform a
deletion analysis in both known HHT genes, as
described above. Southern blot analysis revealed a
deletion of approximately 10kb (fig. 2). The
 further analysis proved that the deletion spans
 exactly 10064 base pairs on the endoglin gene
 including exon 1 (fig. 2). 
Discussion
The 10 kb deletion segregates with the dis-
ease in the family (Fig. 1), whereas the initially de-
tected mutation does not. This prompts the con-
clusion that: (1) the two mutations are probably
biallelic in the grandmother, since they do not
cosegregate (crossing over is very unlikely within
a region of some 22kb, which is the distance
 between the deletion and the point mutation) 
and (2) the mutation c.392C>T is probably not
causative of disease. This finding is concordant
with the HHT Mutation Database (http://
137.195.14.43/cgibin/WebObjects/hht.woa/2/wo
/qaLwSLQJJO2gIUSR3HWEIg
/8.3.17.8.18), which declares the variation
c.392C>T as a rare polymorphism, a finding
which is also supported by Abdalla et al. [1].
Moreover, family member II-2, who has both the
10 kb deletion and the point mutation, does not
present more severe HHT symptoms than IV-2.
Thus, the intrafamilial variability does not depend
on the presence of c.392C>T in the endoglin
gene.
Our analysis identified a large deletion affect-
ing exon 1 (including the ATG codon) of the en-
doglin gene. A similar deletion, also affecting exon
1, has already been described as causative of dis-
ease [11]. Since there is no alternative ATG codon
we predict that no protein is built from the allele
with the 10kb deletion. The fact that members of
this family present so different degrees of HHT
symptoms (the grandmother has had telangiec-
tases since the age of 35 and an AVM of the gas-
trointestinal tract diagnosed at the age of 40, the
mother remained without symptoms until the age
of 26, and the girl has been severely affected since
birth) proves that no prediction based on molecu-
lar analysis can be made even in members of the
same family. Moreover, c.392C>T in the endoglin
gene is probably not connected to HHT in this
family. Also, it cannot be assumed that patients
with large deletions are more severely affected
than patients with missense mutations. Since the
affected girl is the only member in the family with
symptoms since childhood we assume that she
could have inherited a modifying polymorphism
from her father. Hence we also obtained a blood
probe from him, in order to check for sequence
variants on genomic DNA level. Sequence analy-
sis and deletion analysis for both endoglin and
ACVRL1 did not reveal any amino-acid alter-
ation, nonsense mutation or large rearrangement.
A reason for the severe form of HHT in IV-2
could thus be an additional inherited sequence
variant from the father in the promoter region of
the gene (not tested in our analysis) or a mutation
in another modifier gene, which leads to a severe
phenotype only when it is combined with a muta-
tion in endoglin or ACVRL1. This hypothesis, in
our case postulated for HHT, has been proven for
other diseases [12, 13].
In conclusion, we report on a family with a
highly variable HHT phenotype, including an
 unusual phenotype in a child. Several cases of
children with HHT have been described in the
literature [14]. Our case, involving this extreme
intrafamilial variability in phenotype, adds to
identical descriptions in the literature [e.g. 15] and
points to the fact that severe HHT cases may
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occur even in families with otherwise mildly af-
fected individuals. Although the reason for this
phenomenon could not be explained by our
analyses, we would like to point out that the mo-
lecular diagnosis of HHT should include analysis
of both endoglin and ACVRL1. Even when a mu-
tation is found, sequencing should be completed
for every exon of these genes and every positive
result should be proved on further affected and
non-affected members of the family. If this proce-
dure is not followed it is possible that a mutation
will be falsely declared as causative of disease in a
family, resulting in wrong predictive diagnostics
for at-risk members.
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